SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...
Objectives Maternal dietary practices are vital for improving maternal and neonatal outcomes. However, comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results